Clario

The acquisition aims to enhance drug development capabilities and accelerate clinical research innovation.

Thermo Fisher stock trades above its consensus target while Q2 2026 revenue and earnings growth, plus higher debt from the Clario acquisition, frame the next phase for the life-science giant.

/PRNewswire/ -- Clario Group, a global strategic integrated communications and advisory firm, today announced the acquisition of Ted Miller Group (TMG), a...

Thermo Fisher Scientific Inc. (TMO) is up 4.1% today. Here is some analysis on what might have caused this price movement.Analysis: There does not appear to be a single same-day company announcement driving the move, so the gain likely reflects improving

/PRNewswire/ -- Clario Group today announced the launch of XROI (Executive Reputation & Opportunity Index), a proprietary, AI-enabled analytical framework...

Thermo Fisher Scientific has completed the acquisition of Clario, a clinical trial endpoint data solutions supplier, in an $8.875bn deal.

Thermo Fisher plans to create a fast-growing business by integrating Clario's data capture and management system with its existing capabilities.

Thermo Fisher completed the $8.875 billion cash acquisition of Clario, adding endpoint data solutions to its biopharma services.Key Highlights:Original SEC Filing: THERMO FISHER SCIENTIFIC INC. TMO - 8-K - Mar. 24, 2026This is an AI-powered summary. It ma

Clario's platform has supported about 70% of FDA and EMA novel drug approvals over the past decade. Thermo Fisher sees $0.45 EPS in year 1.